Enroxil Max Solution for Injection

Main information

  • Trade name:
  • Enroxil Max Solution for Injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Enroxil Max Solution for Injection
    Romania
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • enrofloxacin
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0312/001
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0312/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:January2013

AN:01156/2012

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

EnroxilMax100mg/mlsolutionforInjectionforCattle

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance:

Enrofloxacin100mg

Excipients:

Benzyl

alcohol

(E1519) 20mg

Butylalcohol 30mg

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,yellowsolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Cattle.

4.2Indicationsforuse,specifyingthetargetspecies

TreatmentofbovinerespiratorydiseaseassociatedwithMannheimia

haemolytica,Pasteurellamultocida,HistophilussomniandMycoplasmaspp.

whereclinicalexperience,supportedwherepossiblebysensitivitytestingof

thecausalorganism,indicatesenrofloxacinasthedrugofchoice.

Treatmentoflocalsigns(inflammation,milkqualityandyield)associatedwith

peracute/acutemastitisinlactatingdairycattlecausedbyE.coli,whereherd

historyandprevioussensitivitytestingindicateenrofloxacinasthedrugof

choice.

4.3Contraindications

Donotuseforprophylaxis.

Donotadministerincaseofhypersensitivitytotheactivesubstanceortoany

oftheexcipients.

Revised:January2013

AN:01156/2012

Page2of5

4.4Specialwarningforeachtargetspecies

None.

4.5Specialprecautionsforuse

i.Specialprecautionsforuseinanimals

Normalsterileprecautionsshouldbetaken.

Thesafetyoftheproducthasnotbeenestablishedincalveswhen

administeredbytheintravenousrouteanduseofthisrouteof

administrationincalvesisthereforenotrecommended.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccount

whentheproductisused.

Fluoroquinolonesshouldbereservedforthetreatmentofclinical

conditionswhichhaverespondedpoorly,orareexpectedtorespond

poorly,tootherclassesofantimicrobials.

Wheneverpossible,fluoroquinolonesshouldonlybeusedbasedon

susceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmay

increasetheprevalenceofbacteriaresistanttothefluoroquinolones

andmaydecreasetheeffectivenessoftreatmentwithotherquinolones

duetothepotentialforcrossresistance.

ii.Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Thisproductisanalkalinesolution.Anyspillageontotheskinshould

bewashedoffimmediatelywithwater.

Intheeventofaccidentalsplashintotheeye,rinsewithcopious

amountsofcleanwater.Ifirritationoccurs,seekmedicaladvice.

Donoteat,drinkorsmokewhilstusingtheproduct.

Careshouldbetakentoavoidaccidentalself-injection.Incaseof

accidentalselfinjection,seekmedicaladviceimmediatelyandshowthe

packageleafletorthelabeltothephysician.

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoid

contactwiththeveterinarymedicinalproduct.

4.6Adversereactions(frequencyandseriousness)

Transientlocalreactionsmayoccuratinjectionsite.

4.7Useduringpregnancy,lactationorlay

Canbeusedduringpregnancyandlactation.

4.8Interactionwithothermedicinalproductsandotherformofinteraction

Noneknown.

Revised:January2013

AN:01156/2012

Page3of5

4.9Amountstobeadministeredandadministrationroute

Toensureacorrectdosage,bodyweightshouldbedeterminedasaccurately

aspossibletoavoidunderdosing.

Dosageanddurationoftreatment:

Forrespiratoryinfectionsincattle:administerbysubcutaneousinjection:

Asingledoseof7.5mg/kgbodyweight(7.5mlper100kgbodyweight)

Notmorethan15mlshouldbeadministeredatonesubcutaneousinjectionsite.

ForE.colimastitisincattle:administerbyslowintravenousinjection.

5.0mlper100kgbodyweight(5mgenrofloxacinperkgbodyweight)dailyfor2

days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Adoseof25mg/kgbodyweightadministeredfor15consecutivedaysis

toleratedwithoutanyclinicalsymptoms.

Clinicalsignsseeningrossoverdosageincludelethargy,lameness,ataxia,

slightsalivationandmuscletremors.Inaccidentaloverdosethereisnoantidote

andtreatmentshouldbesymptomatic.

4.11Withdrawalperiods

Subcutaneoususe:

Meatandoffal: 14days

Milk: 84hours

Intravenoususe:

Meatandoffal: 4days

Milk: 72hours

5.PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse

ATCVetCode:QJ01MA90

5.1Pharmacodynamicproperties

ItisbactericidalinactionwithactivityagainstmanyGrampositiveandGram

negativebacteriaandmycoplasmas.Themechanismofactionofthe

quinolonesisuniqueamongantimicrobials –theyactprimarilytoinhibit

bacterialDNAgyrase,anenzymeresponsibleforcontrollingthesupercoilingof

bacterialDNAduringreplication.Resealingofthedoublestrandedhelixis

inhibitedresultinginirreversibledegradationofthechromosomalDNA.The

fluoroquinolonesalsopossessactivityagainstbacteriainthestationaryphase

byanalterationofthepermeabilityoftheoutermembranephospholipidcellwall

butareinactiveagainststrictanaerobes.

Revised:January2013

AN:01156/2012

Page4of5

Molecularresistancetofluoroquinoloneshasbeenobservedtoarisefromtwo

principalsources,(i)alterationtoDNAgyraseortopoisomeraseIVand(ii)

alterationsindrugpermeabilityofthebacterialcell.Bothmechanismsleadtoa

reducedsusceptibilityofthebacteriatofluoroquinolones.Clinicalresistanceis

dependentonseveralmutationsaccumulatinginastep-wisemanner.

5.2Pharmacokineticparticulars

Thepharmacokineticsofenrofloxcacinissuchthatoralandparenteral

administrationleadstosimilarserumlevels.Enrofloxacinislipidsolubleand

amphotericandpossessesahighdistributionvolume.Tissuelevels2-3higher

thanthatfoundintheserum,havebeendemonstratedinlaboratoryanimals

andtargetspecies.Organsinwhichhighlevelscanbeexpectedarethelungs,

liver,kidney,skin,boneandlymphaticsystem.Enrofloxacinalsodistributesinto

thecerebrospinalfluid,theaqueoushumourandthefoetusinpregnantanimals.

Aftersubcutaneousadministrationof7.5mg/kgthemeanpeakplasma

concentrationis0.8µg/mlachievedwithin6hours.Enrofloxacinispartly

metabolizedintheliver.Approximately45percentofthedoseisexcretedin

theurineand55percentinthefaecesasactiveandmetabolites.

Afteranintravenousdoseof5mgenrofloxacinperkgbodyweight(bw)to

lactatingdairycattle,thetotalsystemicexposureoverthedosingintervalof24

hwasat7.1mg*h/L.Incattleserum,approximately30%ofdrugexposure(2.31

mg*h/L)consistedofciprofloxacin,theactivemetaboliteofenrofloxacin.The

drugwaswelldistributedintothebodycompartments(Venro=1.5L/kg,Vcipro

=8.51L/kg).Totalbodyclearancewas0.71L/h/kg.

Inmilk,mostofdrugactivityconsistedofciprofloxacin.Overalldrug

concentrationspeakedat4.1mg/kgtwohoursaftertreatment.Overalldrug

exposureover24hwas22.1mg*h/L.Theactiveswereeliminatedfrommilk

withameanexposurehalf-lifeof2.8h.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol(E1519)

Butylalcohol

L-Arginine

Waterforinjection

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmust

notbemixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackageforsale:5years.

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days.

Revised:January2013

AN:01156/2012

Page5of5

6.4Specialprecautionsforstorage

Keepthecontainerintheoutercartoninordertoprotectfromlight.

Donotfreeze.

6.5Natureandcompositionofimmediatepackaging

AmberglassType2multi-dosevialsof100mlwithbromobutylrubber

stopper.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements

7.MARKETINGAUTHORISATIONHOLDER

KrkaDd

ŠmarješkaCesta6

NovoMesto

8501

Slovenia

8.MARKETINGAUTHORISATIONNUMBER

Vm

01656/4006

9.DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Date:01August2007

10.DATEOFTHEREVISIONOFTHETEXT

Date:January2013

Prohibitionofsale,supplyand/oruse:

Notapplicable.

Approved:

30/01/13

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Peer review of the pesticide risk assessment of the active substance alpha‐cypermethrin

Peer review of the pesticide risk assessment of the active substance alpha‐cypermethrin

Published on: Mon, 10 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Belgium and co‐rapporteur Member State Greece for the pesticide active substance alpha‐cypermethrin are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration